{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:14:19Z","timestamp":1772050459931,"version":"3.50.1"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>The correlation between spironolactone usage and cancer risk has sparked interest. The objective of this study is to examine the association between spironolactone use and the incidence of urinary tract cancer in the general population.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a matched population-based cohort study. The study population was obtained from the Taiwan National Health Insurance Research Database (TNHIRD) during the period from 2000 to 2016. The multivariate Cox proportional hazard model was performed to examine the impact of spironolactone use on the risk of urinary tract cancer. A total of 8,608 individuals exposed to spironolactone were exact matched by 1:1 ratio with unexposed controls on factors including age, gender, comorbidities, CCI scores and socioeconomic status. The incidences of urinary tract cancer, including prostate, renal and bladder cancer, were estimated in both spironolactone exposed and non-exposed cohorts.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>After adjusting for confounding variables, the multivariate Cox regression analysis showed no significant association between spironolactone exposure and urinary tract cancer incidence, including bladder (adjusted hazard ratio [aHR] = 1.19, 95% confidence interval [CI] = 0.72\u20131.96, p = 0.50), renal (aHR = 1.75, 95% CI = 0.99\u20133.07, p = 0.053), and prostate cancer (aHR = 0.67, 95% CI = 0.43\u20131.04, p = 0.07). When the population was stratified into low (cumulative dose &lt; = 29,300 mg) and high (cumulative dose &gt;29,300 mg) dose of spironolactone, only high dose of spironolactone use was significantly associated with a reduced risk of prostate cancer (aHR = 0.45, 95% CI = 0.23\u20130.89, p = 0.02), while being associated with an elevated risk of renal cancer (aHR = 2.09, 95% CI = 1.07\u20134.08, p = 0.03). However, no clear cumulative dose-response relationship was observed in theses associations.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>High cumulative dose of spironolactone may be potentially associated with a decreased incidence of prostate cancer and an increased incidence of renal cancer, while no significant association was observed with bladder cancer incidence. However, given the lack of support from the dose-response pattern, the available evidence is inconclusive to establish a definitive association between spironolactone use and urinary tract cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0300391","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T17:50:14Z","timestamp":1711561814000},"page":"e0300391","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study"],"prefix":"10.1371","volume":"19","author":[{"given":"Liang-Cheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7819-0535","authenticated-orcid":true,"given":"Hsuan-Ju","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben-Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon-Sing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hon-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yen","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai-Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hui","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4945-528X","authenticated-orcid":true,"given":"Shih-Kai","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"issue":"10","key":"pone.0300391.ref001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"B Pitt","year":"1999","journal-title":"The New England journal of medicine"},{"issue":"4","key":"pone.0300391.ref002","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/MEG.0000000000001678","article-title":"Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver","volume":"32","author":"R Sehgal","year":"2020","journal-title":"European journal of gastroenterology & hepatology"},{"issue":"3","key":"pone.0300391.ref003","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc.2016.4","article-title":"Aspirin and colorectal cancer: the promise of precision chemoprevention.","volume":"16","author":"DA Drew","year":"2016","journal-title":"Nature reviews Cancer"},{"issue":"3","key":"pone.0300391.ref004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1056\/NEJM199101173240304","article-title":"An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987).","volume":"324","author":"UC Dubach","year":"1991","journal-title":"The New England journal of medicine"},{"issue":"5","key":"pone.0300391.ref005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bcpt.12946","article-title":"Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations.","volume":"122","author":"A Potteg\u00e5rd","year":"2018","journal-title":"Basic & clinical pharmacology & toxicology"},{"issue":"7","key":"pone.0300391.ref006","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrurol.2011.79","article-title":"Differing levels of testosterone and the prostate: a physiological interplay.","volume":"8","author":"SL Goldenberg","year":"2011","journal-title":"Nature reviews Urology"},{"issue":"1","key":"pone.0300391.ref007","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/HJH.0000000000001130","article-title":"Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study","volume":"35","author":"YW Chuang","year":"2017","journal-title":"Journal of hypertension"},{"issue":"5","key":"pone.0300391.ref008","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0022-4731(88)90295-6","article-title":"Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture.","volume":"31","author":"IA Luthy","year":"1988","journal-title":"Journal of steroid biochemistry"},{"issue":"4","key":"pone.0300391.ref009","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/bcp.14568","article-title":"Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study","volume":"87","author":"BM Hiebert","year":"2021","journal-title":"British journal of clinical pharmacology"},{"issue":"3","key":"pone.0300391.ref010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamadermatol.2021.5866","article-title":"Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.","volume":"158","author":"K Bommareddy","year":"2022","journal-title":"JAMA dermatology"},{"issue":"3","key":"pone.0300391.ref011","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bcp.13152","article-title":"Spironolactone use and risk of incident cancers: a retrospective, matched cohort study","volume":"83","author":"IS Mackenzie","year":"2017","journal-title":"British journal of clinical pharmacology"},{"issue":"3","key":"pone.0300391.ref012","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1377\/hlthaff.22.3.77","article-title":"Does universal health insurance make health care unaffordable?","volume":"22","author":"JF Lu","year":"2003","journal-title":"Lessons from Taiwan. Health affairs (Project Hope)."},{"issue":"3","key":"pone.0300391.ref013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1377\/hlthaff.22.3.61","article-title":"Taiwan\u2019s new national health insurance program: genesis and experience so far","volume":"22","author":"TM Cheng","year":"2003","journal-title":"Health affairs (Project Hope)"},{"issue":"3","key":"pone.0300391.ref014","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41391-020-0220-8","article-title":"Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study","volume":"23","author":"K Beckmann","year":"2020","journal-title":"Prostate cancer and prostatic diseases"},{"issue":"1","key":"pone.0300391.ref015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"DA Sica","year":"2005","journal-title":"Heart failure reviews"},{"issue":"1","key":"pone.0300391.ref016","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"P Corvol","year":"1975","journal-title":"Endocrinology"},{"issue":"4","key":"pone.0300391.ref017","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/iep.12074","article-title":"Evidence for aldosterone-dependent growth of renal cell carcinoma","volume":"95","author":"S King","year":"2014","journal-title":"International journal of experimental pathology"},{"issue":"4","key":"pone.0300391.ref018","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/HJH.0b013e3282f3ef5e","article-title":"Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials","volume":"26","author":"CI Coleman","year":"2008","journal-title":"Journal of hypertension"},{"issue":"9","key":"pone.0300391.ref019","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1093\/nar\/gku217","article-title":"A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair","volume":"42","author":"OD Shahar","year":"2014","journal-title":"Nucleic acids research"},{"issue":"1","key":"pone.0300391.ref020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"KM Dale","year":"2006","journal-title":"Jama"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0300391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T17:50:33Z","timestamp":1711561833000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0300391"}},"subtitle":[],"editor":[{"given":"Kristina","family":"Kusche-Vihrog","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0300391","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}